Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
Neurocrine Biosciences (NBIX) has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for February 6, 2025. The earnings press release will be issued at 1:00 PM PT, followed by a conference call at 1:30 PM PT. The company, a leading neuroscience-focused biopharmaceutical firm, focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders.
The company's portfolio includes FDA-approved treatments for tardive dyskinesia, Huntington's disease chorea, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids. Additionally, they maintain multiple compounds in mid- to late-phase clinical development across their core therapeutic areas.
Neurocrine Biosciences (NBIX) ha programmato la conferenza e il webcast per i risultati finanziari del quarto trimestre e dell'anno 2024 per il 6 febbraio 2025. Il comunicato stampa sugli utili sarà pubblicato alle 13:00 PT, seguito da una conferenza telefonica alle 13:30 PT. L'azienda, una delle principali aziende biofarmaceutiche focalizzate sulle neuroscienze, si concentra sullo sviluppo di trattamenti per disturbi neurologici, neuroendocrini e neuropsichiatrici.
Il portafoglio dell'azienda include trattamenti approvati dalla FDA per la discinesia tardiva, la corea di Huntington, l'iperplasia surrenalica congenita classica, l'endometriosi e i fibromi uterini. Inoltre, mantengono numerosi composti in sviluppo clinico dalla fase intermedia a quella avanzata nelle loro aree terapeutiche principali.
Neurocrine Biosciences (NBIX) ha programado su conferencia de resultados financieros del cuarto trimestre y del año 2024 y su transmisión en línea para el 6 de febrero de 2025. El comunicado de prensa de ganancias se emitirá a la 1:00 PM PT, seguido de una conferencia telefónica a la 1:30 PM PT. La empresa, una destacada firma biofarmacéutica centrada en las neurociencias, se dedica al desarrollo de tratamientos para trastornos neurológicos, neuroendocrinos y neuropsiquiátricos.
El portafolio de la empresa incluye tratamientos aprobados por la FDA para la discinesia tardía, la corea de Huntington, la hiperplasia suprarrenal congénita clásica, la endometriosis y los fibromas uterinos. Además, mantienen múltiples compuestos en desarrollo clínico en fase media a avanzada en sus áreas terapéuticas clave.
Neurocrine Biosciences (NBIX)는 2024년 4분기 및 연말 재무 결과 컨퍼런스 콜과 웹캐스트를 2025년 2월 6일로 예정했습니다. 수익 보도 자료는 오후 1시(PT)에 발표되며, 이어서 오후 1시 30분(PT)에 컨퍼런스 콜이 진행됩니다. 회사는 신경 과학에 중점을 둔 주요 바이오 제약 회사로, 신경학적, 신경내분비, 신경정신과적 질환 치료제를 개발하는 데 주력하고 있습니다.
회사의 포트폴리오는 지연성 운동 장애, 헌팅턴병 춤, 고전적 선천성 부신 과형성, 자궁내막증 및 자궁 섬유종에 대해 FDA 승인된 치료제를 포함합니다. 또한, 그들은 핵심 치료 분야에서 중기에서 후기 단계의 임상 개발 중인 여러 화합물을 보유하고 있습니다.
Neurocrine Biosciences (NBIX) a programmé sa conférence téléphonique et son webcast sur les résultats financiers du quatrième trimestre et de l'année 2024 pour le 6 février 2025. Le communiqué de presse sur les bénéfices sera publié à 13h00 PT, suivi d'une conférence téléphonique à 13h30 PT. L'entreprise, une société biopharmaceutique de premier plan axée sur les neurosciences, se concentre sur le développement de traitements pour les troubles neurologiques, neuroendocriniens et neuropsychiatriques.
Le portefeuille de l'entreprise comprend des traitements approuvés par la FDA pour la dyskinésie tardive, la chorée de Huntington, l'hyperplasie surrénalienne congénitale classique, l'endométriose et les fibromes utérins. De plus, ils maintiennent plusieurs composés en développement clinique de phase intermédiaire à avancée dans leurs domaines thérapeutiques clés.
Neurocrine Biosciences (NBIX) hat seine Konferenz für die Finanzresultate des vierten Quartals und des Jahres 2024 sowie den Webcast für den 6. Februar 2025 angesetzt. Die Pressemitteilung zu den Ergebnissen wird um 13:00 Uhr PT veröffentlicht, gefolgt von einer Telefonkonferenz um 13:30 Uhr PT. Das Unternehmen, ein führendes biopharmazeutisches Unternehmen mit Schwerpunkt Neurowissenschaften, konzentriert sich auf die Entwicklung von Behandlungen für neurologische, neuroendokrine und neuropsychiatrische Erkrankungen.
Das Portfolio des Unternehmens umfasst von der FDA zugelassene Behandlungen für tardive Dyskinesie, Chorea Huntington, klassische kongenitale adrenale Hyperplasie, Endometriose und Uterusmyome. Darüber hinaus halten sie mehrere Verbindungen in der klinischen Entwicklung von der mittleren bis zur späten Phase in ihren wichtigen Therapiegebieten.
- Diverse portfolio of FDA-approved treatments across multiple conditions
- Multiple compounds in mid to late-phase clinical development
- None.
Conference Call and Webcast Scheduled for Thursday, February 6
The schedule for the press release and conference call / webcast is as follows:
- Q4 & Year-End 2024 Press Release: February 6, 2025 at 1:00 p.m. PT / 4:00 p.m. ET
- Q4 & Year-End 2024 Conference Call: February 6, 2025 at 1:30 p.m. PT / 4:30 p.m. ET
- Domestic Dial-In Number: 800-225-9448
- International Dial-In Number: 203-518-9708
- Conference ID: NBIX
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook.
(*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-end-2024-financial-results-302364771.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When will NBIX release its Q4 and year-end 2024 financial results?
How can investors access NBIX's Q4 2024 earnings call?
What therapeutic areas does NBIX focus on?
Which FDA-approved treatments are in NBIX's current portfolio?
